CA2658222A1 - Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators - Google Patents

Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators Download PDF

Info

Publication number
CA2658222A1
CA2658222A1 CA002658222A CA2658222A CA2658222A1 CA 2658222 A1 CA2658222 A1 CA 2658222A1 CA 002658222 A CA002658222 A CA 002658222A CA 2658222 A CA2658222 A CA 2658222A CA 2658222 A1 CA2658222 A1 CA 2658222A1
Authority
CA
Canada
Prior art keywords
group
cells
cell activator
cell
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002658222A
Other languages
English (en)
French (fr)
Inventor
Jean-Jacques Fournie
Julie Gertner
Helene Sicard
Guy Laurent
Christine Bezombes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Innate Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2658222A1 publication Critical patent/CA2658222A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002658222A 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators Abandoned CA2658222A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06291146A EP1878440A1 (en) 2006-07-13 2006-07-13 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
EP06291146.6 2006-07-13
US92420807P 2007-05-03 2007-05-03
US60/924,208 2007-05-03
PCT/EP2007/057217 WO2008006895A2 (en) 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators

Publications (1)

Publication Number Publication Date
CA2658222A1 true CA2658222A1 (en) 2008-01-17

Family

ID=37708304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002658222A Abandoned CA2658222A1 (en) 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using .gamma. .delta. t cell activators

Country Status (6)

Country Link
US (1) US20090304688A1 (enExample)
EP (2) EP1878440A1 (enExample)
JP (1) JP2009544582A (enExample)
AU (1) AU2007274295A1 (enExample)
CA (1) CA2658222A1 (enExample)
WO (1) WO2008006895A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008146167A2 (en) * 2007-06-01 2008-12-04 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
CN112930187A (zh) * 2018-09-27 2021-06-08 弗斯弗加姆股份有限公司 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
CN109529050A (zh) * 2018-12-07 2019-03-29 广州市妇女儿童医疗中心 Vγ9δ2T细胞、治疗肺癌的药物ZOL和hMSH2协同作用的应用
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CA3211627A1 (en) * 2021-03-11 2022-09-15 Stanley Hersh Appel Methods and compositions for treatment of disease
CN117264904A (zh) * 2023-09-18 2023-12-22 北京大学第三医院（北京大学第三临床医学院） 一种靶向HER2的γδT细胞及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
CN1890252A (zh) * 2003-12-02 2007-01-03 依奈特制药公司 新类型的γδT细胞活化剂及其应用
EP1738538B1 (en) * 2004-01-06 2018-08-08 Vasu Networks Corporation Telephone with automatic switching between cellular and voip networks
ATE419008T1 (de) * 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT

Also Published As

Publication number Publication date
EP1878440A1 (en) 2008-01-16
AU2007274295A1 (en) 2008-01-17
JP2009544582A (ja) 2009-12-17
WO2008006895A3 (en) 2008-03-27
US20090304688A1 (en) 2009-12-10
EP2040750A2 (en) 2009-04-01
WO2008006895A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
US20090304688A1 (en) Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators
JP7860182B2 (ja) 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
TWI838196B (zh) 抗cd38抗體之皮下調配物及其用途
JP6816038B2 (ja) 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
EP4653463A2 (en) Antibodies
US20210330642A1 (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
CA3090236A1 (en) Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
RU2723937C2 (ru) Композиции, включающие антитела к cd38 и карфилзомиб
TW201617093A (zh) 對抗ｐｄ－１及ｐｄ－ｌ１之拮抗劑與輻射療法組合之治療方法
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
US20100189681A1 (en) Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer
US20230134748A1 (en) Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
US20260130906A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
JP2019524780A (ja) プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ
TWI724046B (zh) 以抗ｃｄ３８抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
HK40015605B (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130712